{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-007660","form_type":"8-K","ticker":"CODX","cik":"0001692415","company_name":"Co-Diagnostics, Inc.","filed_at":"2022-03-24T23:59:59+00:00","discovered_at":"2026-05-14T18:04:07.838114+00:00","generated_at":"2026-06-26T18:32:33.630155+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Co-Diagnostics reports FY2021 revenue $97.9M, EPS $1.23; guides Q1 FY2022 revenue $21-22M","bullets":["Revenue $97.9M, +$23.3M YoY; net income $36.7M ($1.23 diluted EPS) vs $42.5M ($1.52) in 2020.","Adjusted EBITDA $52.1M, up from $45.3M in 2020; cash & securities $89.9M at Dec 31, 2021.","Q1 FY2022 guidance: revenue $21-22M, diluted EPS $0.17-0.20, shares 32.4M.","Gross profit $86.3M (88.2% margin); operating income $46.1M on record revenue.","2021 highlights: at-home PCR platform, acquisitions of Idaho Molecular & Advanced Conceptions, CDSCO clearance for ABC test in India."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-007660","json":"https://secwatch.observer/filing/0001493152-22-007660.json","markdown":"https://secwatch.observer/filing/0001493152-22-007660.md","text":"https://secwatch.observer/filing/0001493152-22-007660.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/0001493152-22-007660-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1692415/000149315222007660/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T18:32:33.630155+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}